Table 1.

Cohort description.

Characteristics	Pre-COVID-19 era, N = 77	COVID-19 era, N = 54	P
Age, median (IQR)	34.0 (27.0–46.4)	39.9 (28.9–49.9)	.088
Sex n (%)			.267
Male	61 (79.2)	36 (66.7)
Female	12 (15.6)	14 (25.9)
Transgender	4 (5.2)	4 (7.4)
Country, n (%)			.167
Italy	44 (57.1)	31 (57.4)
Africa	12 (15.6)	2 (3.7)
Asia	3 (3.9)	4 (7.4)
Eastern Europe	4 (5.2)	6 (11.1)
South America	14 (18.2)	11 (20.4)
Risk factor, n (%)—∗each patient may have more than one
Men who have sex with men	47 (61.0)	19 (35.2)	.002
Heterosexual	31 (40.3)	31 (57.4)	.077
Intravenous drug use	0 (0)	2 (3.7)	.168
Other	2 (2.6)	4 (7.4)	.674
AIDS-defining illness	24 (31.2)	6 (11.3)	.011
Late presentation	49 (63.6)	31 (57.4)	.004
Screening for SARS-CoV-2		22 (40.7)	—
Positive result		2 (3.7)	—
Nadir CD4+ cell count, median (IQR)	205 (59–432)	305 (157–553)	.026
Zenith HIV-RNA (log10 copies/mL), median (IQR)	5.22 (4.78–5.78)	4.46 (4.09–4.92)	<.001
Symptoms at presentation
Cough	7 (9.1)	6 (11.3)	1
Fever	9 (11.7)	13 (24.1)	.457
Shortness of breath	2 (2.6)	6 (11.3)	.145
Diarrhea	3 (3.9)	3 (5.6)	1
Weight loss	5 (6.5)	11 (20.4)	.060
Rash	2 (2.6)	2 (3.7)	1
Sweats	3 (3.9)	4 (7.4)	.705
Headache	1 (1.4)	1 (1.9)	1
Loss of consciousness	0	1 (1.9)	.481
Asthenia	3 (3.9)	3 (5.6)	1
Other	5 (6.5)	2 (3.7)	.194
First-line antiretrovirals			.712
2NRTI + INI	56 (72.7)	40 (74.1)
2NRTI + PI	9 (11.7)	3 (5.6)
2NRTI + NNRTI	6 (7.8)	5 (9.2)
DTG + 3TC	3 (3.9)	4 (7.4)
Other/none	3 (3.9)	2 (3.7)
Comorbidities
Diabetes	1 (1.4)	2 (3.7)	.386
Hypertension	6 (8.2)	6 (11.3)	.558
Ischemic heart disease	0	0	N/A
Obesity	1 (1.4)	0	.454
Osteoporosis	0	2 (3.7)	.499
Malignancy	5 (6.5)	2 (3.7)	.698
Dyslipidemia	1 (1.4)	4 (7.4)	.161
Chronic kidney disease	0	1 (1.9)	.421
Other	7 (9.1)	0	N/A